

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

1. NAME OF THE MEDICINAL PRODUCT

TEPMETKO 225 mg film-coated tablets

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each film-coated tablet contains 225 mg tepotinib (as hydrochloride hydrate).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Film-coated tablet (tablet).

White-pink, oval, biconvex film-coated tablet of approximately 18 x 9 mm in size, embossed with 'M' on one side and plain on the other side.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications

TEPMETKO as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (*MET*ex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

4.2 Posology and method of administration

Treatment must be initiated and supervised by a physician experienced in the use of anticancer therapies.

Prior to initiation of treatment with TEPMETKO the presence of *MET*ex14 skipping alterations should be confirmed by a validated test method (see sections 4.4 and 5.1).

Posology

The recommended dose is 450 mg tepotinib (2 tablets) taken once daily. Treatment should continue as long as clinical benefit is observed.

If a daily dose is missed, it can be taken as soon as remembered on the same day, unless the next dose is due within 8 hours.

Dose modification for adverse reactions

The recommended dose reduction level for the management of adverse reactions is 225 mg (1 tablet) daily. Detailed recommendations for dose modification are provided in the table hereafter.

Table 1: Recommended dose modifications for TEPMETKO

Adverse reaction	Severity	Dose modification
Interstitial lung disease (ILD) (see section 4.4)	Any grade	Withhold TEPMETKO if ILD is suspected. Permanently discontinue TEPMETKO if ILD is confirmed.
Increased ALT and/or AST without increased total bilirubin (see section 4.4)	ALT and/or AST greater than 5 times up to 20 times ULN	Withhold TEPMETKO until recovery to baseline ALT/AST. If recovered to baseline within 7 days, then resume TEPMETKO at the same dose; otherwise resume TEPMETKO at a reduced dose.
	ALT and/or AST greater than 20 times ULN	Permanently discontinue TEPMETKO.
Increased ALT and/or AST with increased total bilirubin in the absence of cholestasis or haemolysis (see section 4.4)	ALT and/or AST greater than 3 times ULN with total bilirubin greater than 2 times ULN	Permanently discontinue TEPMETKO.
Other adverse reactions (see section 4.8)	Grade 3 or higher	Reduce TEPMETKO to 225 mg until the adverse reaction recovers to $\leq$ grade 2. A temporary interruption of TEPMETKO treatment for no more than 21 days can also be considered.

ULN = upper limit of normal

Special populations

Renal impairment

No dose adjustment is recommended in patients with mild or moderate renal impairment (creatinine clearance 30 to 89 mL/min) (see section 5.2). The pharmacokinetics and safety of tepotinib in patients with severe renal impairment (creatinine clearance below 30 mL/min) have not been studied. The use of TEPMETKO in patients with severe renal impairment is therefore not recommended.

Renal function estimates that rely on serum creatinine (creatinine clearance or estimated glomerular filtration rate) should be interpreted with caution (see section 4.4).

Hepatic impairment

No dose adjustment is recommended in patients with mild (Child Pugh Class A) or moderate (Child Pugh Class B) hepatic impairment (see section 5.2). The pharmacokinetics and safety of tepotinib in patients with severe hepatic impairment (Child Pugh Class C) have not been studied. The use of TEPMETKO in patients with severe hepatic impairment is therefore not recommended.

Elderly

No dose adjustment is necessary in patients aged 65 years and above (see section 5.2).

Paediatric population

Safety and efficacy of tepotinib in paediatric patients below 18 years of age have not been established. No data are available.

Method of administration

TEPMETKO is for oral use. The tablet(s) should be taken with food and should be swallowed whole to ensure that the full dose is administered.

If the patient is unable to swallow, the tablets can be dispersed in 30 mL of non-carbonated water. No other liquids should be used or added. The tablets should be dropped in a glass with water without crushing, stir until the tablets dispersed into small pieces which may take a few minutes (the tablet will not completely dissolve). The dispersion should be swallowed within 1 hour. Rinse the glass with additional 30 mL to ensure that no residues remain in the glass and drink immediately.

If an administration via a naso-gastric tube (with at least 8 French gauge) is required, the tablets should be dispersed in 30 mL of non-carbonated water as described above. The 30 mL of liquid should be administered within 1 hour as per naso-gastric tube manufacturer's instructions. Immediately rinse twice with 30 mL each to ensure that no residues remain in the glass or syringe and the full dose is administered.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

4.4 Special warnings and precautions for use

Assessment of *METex14* skipping alterations status

When detecting the presence of alterations leading to *METex14* skipping using tissue-based or plasma-based specimens, it is important that a well-validated and robust test is chosen to avoid false negative or false positive results. For the characteristics of tests used in clinical studies, see section 5.1.

Interstitial lung disease and pneumonitis

Interstitial lung disease (ILD) or ILD-like adverse reactions including pneumonitis have been reported in patients who received tepotinib monotherapy at the recommended dose regimen and may be fatal (see section 4.8).

Patients should be monitored for pulmonary symptoms indicative for ILD-like reactions. TEPMETKO should be withheld and patients should be promptly investigated for alternative diagnosis or specific aetiology of interstitial lung disease. TEPMETKO must be permanently discontinued if interstitial lung disease is confirmed and the patient be treated appropriately.

Monitoring of liver enzymes

Increase in ALT and/or AST have been reported in patients who received tepotinib monotherapy at the recommended dose regimen (see section 4.8).

Liver enzymes (ALT and AST) and bilirubin should be monitored prior to the start of TEPMETKO treatment and thereafter as clinically indicated. If grade 3 or higher increases (ALT and/or AST greater than 5 times ULN) occur, dose adjustment or discontinuation is recommended (see section 4.2).

QTc prolongation

QTc prolongation was reported in a limited number of patients (see section 4.8). In patients at risk of developing QTc prolongation, including patients with known electrolyte disturbances or taking concomitant medicinal products known to have QTc prolongation effects, monitoring is recommended as clinically indicated (e.g. ECG, electrolytes).

Embryo-foetal toxicity

Tepotinib can cause foetal harm when administered to pregnant women. Pregnancy testing is recommended in women of childbearing potential prior to initiating treatment with TEPMETKO. Women of childbearing potential and males with female partners of childbearing potential should use effective contraception during TEPMETKO treatment and for at least 1 week after the last dose (see section 4.6).

Interpretation of laboratory tests

In vitro studies suggest that tepotinib or its main metabolite inhibit the renal tubular transporter proteins organic cation transporter (OCT) 2 and multidrug and toxin extrusion transporters (MATE) 1 and 2 (see section 5.2). Creatinine is a substrate of these transporters, and the observed increases in creatinine (see section 4.8) may be the result of inhibition of active tubular secretion rather than renal injury. Renal function estimates that rely on serum creatinine (creatinine clearance or estimated glomerular filtration rate) should be interpreted with caution considering this effect. In case of blood creatinine increase while on treatment, it is recommended that further assessment of the renal function be performed to exclude renal impairment.

4.5 Interaction with other medicinal products and other forms of interaction

Effects of other medicinal products on tepotinib

CYP and P-gp inducers

Tepotinib is a substrate for P-glycoprotein (P-gp). In healthy participants, co-administration of a single 450 mg tepotinib dose with the strong inducer carbamazepine (300 mg twice daily for 14 days) decreased tepotinib AUC_{inf} by 35% and C_{max} by 11% compared to administration of tepotinib alone. The decreased exposure is not clinically relevant.

Dual strong CYP3A inhibitors and P-gp inhibitors

In healthy participants, co-administration of a single 450 mg tepotinib dose with the strong CYP3A inhibitor and P-gp inhibitor itraconazole (200 mg once daily for 11 days) increased tepotinib AUC_{inf} by 22% with no change in tepotinib C_{max} compared to administration of tepotinib alone. This is classified as a weak interaction, and the observed changes in systemic exposure to tepotinib are not considered clinically relevant. Therefore, CYP3A and P-gp inhibitors are not expected to influence tepotinib exposure.

Acid-reducing agents

Co-administration of omeprazole under fed conditions had no clinically relevant effect on the pharmacokinetic profile of a single dose of tepotinib 450 mg and its metabolites (geometric mean ratio for tepotinib of 110% for AUC_{inf} (90% CI: 102; 119) and of 104% for C_{max} (90% CI: 93; 117); similar effect on metabolites observed).

Effects of tepotinib on other medicinal products

P-gp substrates

Tepotinib is an inhibitor of P-gp. Administration of tepotinib 450 mg orally once daily for 8 days increased the AUC of the sensitive P-gp substrate dabigatran etexilate by approximately 50% and C_{max} by approximately 40%. Dose adjustment of dabigatran etexilate may be needed in case of concomitant use. Caution and monitoring for adverse reactions of other P-gp-dependent substances with a narrow therapeutic index (e.g. digoxin, aliskiren, everolimus, sirolimus) is recommended during co-administration with TEPMETKO.

BCRP substrates

Tepotinib can inhibit the transport of substrates of the breast cancer resistance protein (BCRP) *in vitro* (see section 5.2). Monitoring for adverse reactions of sensitive BCRP substrates (e.g. rosuvastatin, methotrexate, topotecan) is recommended during co-administration with TEPMETKO.

Substrates of OCT and MATE

Based on *in vitro* data, tepotinib or its metabolite may have the potential to alter the exposure of substrates of the transporters OCT1 and 2 and MATE1 and 2 (see section 5.2). The most clinically relevant example of substrates of these transporters is metformin. Monitoring of the clinical effects of metformin is recommended during co-administration with TEPMETKO.

CYP3A4 substrates

Multiple administrations of 450 mg tepotinib orally once daily had no clinically relevant effect on the pharmacokinetics of the sensitive CYP3A4 substrate midazolam.

Hormonal contraceptives

It is currently unknown whether tepotinib may reduce the effectiveness of systemically acting hormonal contraceptives. Therefore, women using systemically acting hormonal contraceptives should add a barrier method during TEPMETKO treatment and for at least 1 week after the last dose (see section 4.6).

4.6 Fertility, pregnancy and lactation

Women of childbearing potential/Contraception in males and females

Pregnancy testing is recommended in women of childbearing potential prior to initiating treatment with TEPMETKO.

Women of childbearing potential should use effective contraception during TEPMETKO treatment and for at least 1 week after the last dose. Women using systemically acting hormonal contraceptives should add a barrier method during TEPMETKO treatment and for at least 1 week after the last dose (see section 4.5).

Male patients with female partners of childbearing potential should use barrier contraception during TEPMETKO treatment and for at least 1 week after the last dose.

Pregnancy

There are no clinical data on the use of tepotinib in pregnant women. Studies in animals have shown teratogenicity (see section 5.3). Based on the mechanism of action and findings in animals tepotinib can cause foetal harm when administered to pregnant women.

TEPMETKO should not be used during pregnancy, unless the clinical condition of the woman requires treatment with tepotinib. Women of childbearing potential or male patients with female partners of childbearing potential should be advised of the potential risk to a foetus.

Breast-feeding

There are no data regarding the secretion of tepotinib or its metabolites in human milk or its effects on the breast-fed child or milk production. Breast-feeding should be discontinued during treatment with TEPMETKO and for at least 1 week after the last dose.

Fertility

No human data on the effect of tepotinib on fertility are available. No morphological changes in male or female reproductive organs were seen in the repeat-dose toxicity studies in rats and dogs, except for reduced secretion in seminal vesicles of male rats at comparable human clinical exposure (see section 5.3).

4.7 Effects on ability to drive and use machines

TEPMETKO has no influence on the ability to drive and use machines.

4.8 Undesirable effects

Summary of the safety profile

The most common adverse reactions in $\geq 20\%$ of exposed to tepotinib at the recommended dose in the target indication (N = 313) are oedema (81.5% of patients), mainly peripheral oedema (72.5%), hypoalbuminaemia (32.9%), nausea (31.0%), increase in creatinine (29.1%) and diarrhoea (28.8%).

The most common serious adverse reactions in $\geq 1\%$ of patients are peripheral oedema (3.2%), generalised oedema (1.9%) and ILD (1.0%).

The percentage of patients who had adverse events leading to permanent treatment discontinuation is 24.9%. The most common adverse reactions leading to permanent discontinuation in $\geq 1\%$ of patients are peripheral oedema (5.4%), oedema (1.3%), genital oedema (1.0%) and ILD (1.0%).

The percentage of patients who had adverse events leading to temporary treatment discontinuation is 52.7%. The most common adverse reactions leading to temporary discontinuation in $\geq 2\%$ of patients are peripheral oedema (19.8%), increase in creatinine (5.8%), generalised oedema (4.8%), oedema (3.8%), increase in ALT (2.9%), nausea (3.2%) and increase in amylase (1.6%).

The percentage of patients who had adverse events leading to dose reduction is 36.1%. The most common adverse reactions leading to dose reduction in $\geq 2\%$ of patients are peripheral oedema (15.7%), increase in creatinine (2.9%), generalised oedema (3.2%) and oedema (2.6%).

List of adverse reactions

Adverse reactions described in the list below reflect exposure to tepotinib in 506 patients with various solid tumours enrolled in five open-label studies, in which patients received tepotinib as a single agent at a dose of 450 mg once daily.

The frequencies of adverse reactions are based on all-cause adverse event frequencies identified in 313 patients exposed to tepotinib at the recommended dose in the target indication, whereas frequencies for changes in laboratory parameters are based on worsening from baseline by at least 1 grade and shifts to $\geq$ grade 3. Median duration of treatment was 7.5 months (range 0 to 72).

Frequencies presented may not be fully attributable to tepotinib alone but may contain contributions from the underlying disease or from other medicinal products used concomitantly.

The severity of adverse reactions was assessed based on the Common Terminology Criteria for Adverse Events (CTCAE), defining grade 1 = mild, grade 2 = moderate, grade 3 = severe, grade 4 = life threatening and grade 5 = death.

The following definitions apply to the frequency terminology used hereafter:

Very common ($\geq 1/10$)

Common ($\geq 1/100$ to $< 1/10$)

Uncommon ($\geq 1/1\ 000$ to $< 1/100$)

Rare ($\geq 1/10\ 000$ to $< 1/1\ 000$)

Very rare ($< 1/10\ 000$)

Frequency not known (cannot be estimated from the available data)

Table 2: Adverse reactions in patients with NSCLC harbouring *MET*ex14 skipping alterations (VISION)

System organ class/Adverse reaction	TEPMETKO N = 313		
	Frequency category	All grades %	Grade ≥ 3 %
<u>Metabolism and nutrition disorders</u>			
Decrease in albumin ^{*,a}	Very common	78.6	8.9
<u>Cardiac disorders</u>			
QT prolongation*	Common	2.6	---
<u>Respiratory, thoracic and mediastinal disorders</u>			
ILD-like reactions ^{*,b,c}	Common	2.6	0.3
<u>Gastrointestinal disorders</u>			
Nausea	Very common	31.0	1.3
Diarrhoea	Very common	28.8	0.6
Increase in amylase ^{*,a}	Very common	24.0	5.1
Increase in lipase ^{*,a}	Very common	20.4	5.1
Vomiting	Very common	14.4	1.0
<u>Hepatobiliary disorders</u>			
Increase in alkaline phosphatase (ALP)*	Very common	50.8	1.6
Increase in alanine aminotransferase (ALT) ^{*,a}	Very common	48.9	4.8
Increase in aspartate aminotransferase (AST) ^{*,a}	Very common	39.3	3.5
<u>Renal and urinary disorders</u>			
Increase in creatinine ^{*,a}	Very common	58.8	1.0
<u>General disorders and administration site conditions</u>			
Oedema ^{*,d}	Very common	81.5	15.7

* Additional information on the respective adverse reaction is provided below

^a Represents the incidence of laboratory findings, not of reported adverse events

^b ILD as per integrated assessment

^c includes terms interstitial lung disease, pneumonitis, acute respiratory failure

^d includes terms oedema peripheral, oedema, generalised oedema, oedema genital, face oedema, localised oedema, periorbital oedema, peripheral swelling, scrotal oedema

Description of selected adverse reactions

Interstitial lung disease

Interstitial lung disease (ILD) or ILD-like reactions have been reported in 8 patients (2.6%), including 1 case of grade 3 or higher; serious cases occurred in 4 patients (1.3%), 1 case was fatal. Treatment was permanently discontinued in 5 patients and temporarily in 3 patients. Median time to onset of ILD was 9.4 weeks. For clinical recommendations, see sections 4.2 and 4.4.

Increase in liver enzymes

ALT and/or AST increase led to permanent treatment discontinuation in 1 patient and infrequently led to temporary discontinuation (3.2%) or dose reduction (0.3%) of tepotinib. Median time to first onset for ALT and/or AST increase of any grade reported as an adverse event by investigators was 9.1 weeks. The median time to resolution was 3.6 weeks, 86% of events resolved. For clinical recommendations, see sections 4.2 and 4.4.

ALP increase did not lead to any dose reductions, temporary treatment discontinuation or permanent discontinuation. The observed ALP increase was not associated with cholestasis. Median time to first onset for ALP increase of any grade reported as an adverse event by investigators was 9.1 weeks. The median time to resolution was 9.1 weeks, 80% of events resolved.

Oedema

The most frequently reported event was peripheral oedema (72.5% of patients), followed by oedema (8.3%) and generalised oedema (6.7%). Median time to onset of any-grade oedema was 9.1 weeks. The median time to resolution was 71 weeks, 39.2% of events resolved. 8% of patients had oedema events leading to permanent treatment discontinuation, of whom 5.4% had peripheral oedema. 28.4% of patients temporarily discontinued treatment and 21.7% of patients had dose reductions due to oedema. Most frequently peripheral oedema led to temporary treatment discontinuation and dose reductions (19.8% and 15.7%, respectively). Generalised oedema events led to a dose reduction in 3.2% of patients, to temporary treatment discontinuation in 4.8% and to permanent discontinuation in 0.6%.

Increase in creatinine

Increase in creatinine led to permanent treatment discontinuation in 2 patients (0.6%), temporary treatment discontinuation in 5.8% of patients and dose reduction in 2.9% of patients. Median time to onset of increase in creatinine reported as an adverse event by investigators was 3.4 weeks. The median time to resolution was 9.1 weeks, 78% of events resolved. The observed increases in creatinine are thought to occur mainly due to inhibition of renal tubular secretion (see section 4.4).

Hypoalbuminaemia

Hypoalbuminaemia appeared to be long-lasting but did not lead to permanent treatment discontinuation. Dose reduction (1.6%) and temporary discontinuation (1.9%) were infrequent. Median time to onset of any-grade hypoalbuminaemia reported as an adverse event by investigators was 9.4 weeks. The median time to resolution was 28.9 weeks, 48% of events resolved.

Increase in amylase or lipase

Increases in amylase or lipase reported as an adverse event by investigators were asymptomatic and not associated with pancreatitis. 3.2% of patients temporarily discontinued treatment and there were no permanent treatment discontinuation or dose reduction. Median time to onset of any grade in lipase/amylase increase was 15 weeks. The median time to resolution was 6.1 weeks, 83% of events resolved.

QTc prolongation

QTcF prolongation to > 500 ms was observed in 8 patients (2.6%) and a QTcF prolongation by at least 60 ms from baseline in 19 patients (6.1%) (see section 4.4). The findings were isolated and asymptomatic; the clinical significance is unknown.

Additional information on special populations

Elderly

Of 313 patients with *MET*ex14 skipping alterations in the VISION study who received 450 mg tepotinib once daily, 79% were 65 years or older, and 8% were 85 years or older. The occurrence of grade ≥ 3 events increased with age. Treatment-related serious events were more frequent in patients aged ≥ 75 years and < 85 years (21%) or those aged ≥ 85 years (20.8%) when compared to those younger than 65 years (10.4%), although this comparison is limited by the small sample size in patients aged ≥ 85 years.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via

Ireland

HPRA Pharmacovigilance

Website: www.hpra.ie

4.9 Overdose

Tepotinib has been investigated at doses up to 1 261 mg, but experience with doses higher than the recommended therapeutic dose is limited.

The symptoms of overdose are expected to be in the range of known adverse reactions (see section 4.8). There is no specific antidote for TEPMETKO. Treatment of overdose is directed to symptoms.

5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antineoplastic agents, other protein kinase inhibitors, ATC code: L01EX21

Mechanism of action

Tepotinib is a reversible Type I adenosine triphosphate (ATP)-competitive small molecule inhibitor of MET. Tepotinib blocked MET phosphorylation and MET-dependent downstream signalling such as the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) and mitogen-activated protein kinase/extracellular-signal regulated kinase (MAPK/ERK) pathways in a dose-dependent manner.

Tepotinib demonstrated pronounced anti-tumour activity in tumours with oncogenic activation of *MET*, such as *MET*ex14 skipping alterations.

Pharmacodynamic effects

Cardiac electrophysiology

A concentration-dependent increase in QTc interval was observed in the concentration-QTc analysis. At the recommended dose, no large mean increases in QTc (i.e. > 20 ms) were detected in patients with various solid tumours. The QTc effect of tepotinib at supratherapeutic exposures has not been evaluated. See sections 4.4. and 4.8.

Detection of *METex14* skipping status

In clinical studies, identification of *METex14* skipping alterations relied on next generation sequencing using RNA or DNA (1 patient) extracted from formalin-fixed paraffin embedded (FFPE) tumour tissue or using circulating cell free DNA from plasma. Additionally, a RNA-based reverse transcriptase polymerase chain reaction-based method specific for detecting *METex14* skipping alterations from fresh frozen tissue was available to patients in Japan.

Clinical efficacy and safety

The efficacy of tepotinib was evaluated in a single-arm, open-label, multicentre study (VISION) in adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harbouring *METex14* skipping alterations (n = 313). Patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1 and were either treatment-naïve or had progressed on up to 2 lines prior systemic therapies. Neurologically stable patients with central nervous system metastases were permitted. Patients with epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) activating alterations were excluded. Patients received tepotinib as first-line (52%), second-line (29%) or later line (18%) therapy.

Patients who received tepotinib for second- or later line therapy (n = 149) had a median age of 71 years (range 41 to 89), 52% were female and 48% male. The majority of patients were white (56%), followed by Asian patients (38%) and were never (53%) or former smokers (40%). Most patients were ≥ 65 years of age (75%) and 35% of patients were ≥ 75 years of age. The majority of patients (95%) had stage IV disease, 81% had adenocarcinoma histology. Thirteen percent of the patients had stable brain metastases. Eighty-four percent of patients had received prior platinum-based cancer therapy and 54% of patients had received immune-based cancer therapy, including 40% of patients who had received immunotherapy as monotherapy. *METex14* skipping was prospectively detected by testing from tumour tissue in 65% of patients and by testing from plasma in 56% of patients; 56% of patients tested positive with both methods.

Patients received 450 mg tepotinib once daily until disease progression or unacceptable toxicity. Median treatment duration was 7.5 months (range 0 to 72). The follow-up time was at least 18 and up to 72 months at the time of the data cut-off (cut-off date 20 November 2022).

The primary efficacy outcome measure was confirmed objective response (complete response or partial response) according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) as evaluated by an Independent Review Committee (IRC). Additional efficacy outcome measures included duration of response and progression-free survival assessed by IRC as well as overall survival.

Table 3: Clinical outcomes in the VISION study by IRC assessment

Efficacy parameter	Overall population N = 313	Previously treated patients N = 149
Objective response rate (ORR), % ^a	51.4	45.0
[95% CI]	[45.8, 57.1]	[36.8, 53.3]
Median duration of response (mDoR), months ^b	18.0	12.6
[95% CI]	[12.4, 46.4]	[9.5, 18.5]

IRC = Independent Review Committee, CI = confidence interval

^a Only includes partial response

^b Product-limit (Kaplan-Meier) estimates, 95% CI for the median using the Brookmeyer and Crowley method

Efficacy outcome was independent of the testing modality (in plasma or tumour specimens) used to establish the *METex14* skipping status. Consistent efficacy results in subgroups by prior therapy, presence of brain metastasis or age were observed.

Paediatric population

The European Medicines Agency has waived the obligation to submit the results of studies with TEPMETKO in all subsets of the paediatric population in treatment of non-small cell lung cancer (NSCLC) (see section 4.2 for information on paediatric use).

5.2 Pharmacokinetic properties

Absorption

A mean absolute bioavailability of 71.6% was observed for a single 450 mg dose of tepotinib administered in the fed state; the median time to C_{max} was 8 hours (range from 6 to 12 hours).

The presence of food (standard high-fat, high-calorie breakfast) increased the AUC of tepotinib by about 1.6-fold and C_{max} by 2-fold.

Distribution

In human plasma, tepotinib is highly protein bound (98%). The mean volume of distribution (V_z) of tepotinib after an intravenous tracer dose (geometric mean and geoCV%) was 574 L (14.4%).

Biotransformation

Overall, metabolism is a major route of elimination, but no single metabolic pathway accounted for more than 25% of tepotinib elimination. Only one major circulating plasma metabolite has been identified, MSC2571109A. There is only a minor contribution of the major circulating metabolite to the overall efficacy of tepotinib in humans.

In-vitro pharmacokinetic interaction studies

Effects of tepotinib on other transporters: Tepotinib or its major circulating metabolite inhibit P-gp, BCRP, OCT1 and 2 and MATE1 and 2 at clinically relevant concentrations. At clinically relevant concentrations tepotinib presents no risk for organic-anion-transporting polypeptide (OATP) 1B1 and OATP1B3 or organic anion transporter (OAT) 1 and 3.

Effects of tepotinib on UDP-glucuronosyltransferase (UGT): Tepotinib is an inhibitor of UGT1A9 at clinically relevant concentrations, but the clinical relevance is unknown. Tepotinib and its major circulating metabolite are not inhibitors of the other isoforms (UGT1A1/3/4/6 and 2B7/15/17) at clinically relevant concentrations.

Effect of tepotinib on CYP 450 enzymes: At clinically relevant concentrations neither tepotinib nor the major circulating metabolite represent a risk of inhibition of CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP2E1. Tepotinib or its major circulating metabolite do not induce CYP1A2 and 2B6.

Elimination

After intravenous administration of single doses, a total systemic clearance (geometric mean and geoCV%) of 12.8 L/h was observed.

After a single oral administration of a radiolabelled dose of 450 mg tepotinib, tepotinib was mainly excreted via the faeces (approximately 78% of the dose was recovered in faeces), with urinary excretion being a minor excretion pathway.

Biliary excretion of tepotinib is a major elimination pathway. The unchanged tepotinib represented 45% and 7% of the total radioactive dose in faeces and urine, respectively. The major circulating metabolite accounted for only about 3% of the total radioactive dose in the faeces.

The effective half-life for tepotinib is approximately 32 h. After multiple daily administrations of 450 mg tepotinib, median accumulation was 2.5-fold for C_{max} and 3.3-fold for AUC_{0-24h} .

Dose and time dependence

Tepotinib exposure increases approximately dose-proportionally over the clinically relevant dose range up to 450 mg. The pharmacokinetics of tepotinib did not change with respect to time.

Special populations

A population kinetic analysis did not show any clinically meaningful effect of age (range 18 to 89 years), race, gender or body weight, on the pharmacokinetics of tepotinib. Data on ethnicities other than Caucasian or Asian are limited.

Renal impairment

There was no clinically meaningful change in exposure in patients with mild and moderate renal impairment. Patients with severe renal impairment (creatinine clearance less than 30 mL/min) were not included in clinical studies.

Hepatic impairment

Following a single oral dose of 450 mg, tepotinib exposure was similar in healthy subjects and patients with mild hepatic impairment (Child-Pugh Class A) and was slightly lower (13% lower AUC and 29% lower C_{max}) in patients with moderate hepatic impairment (Child-Pugh Class B) compared to healthy subjects. Based on unbound tepotinib concentrations, AUC was about 13% and 24% higher in patients with mild and moderate hepatic impairment, respectively, compared to healthy subjects. The pharmacokinetics of tepotinib have not been studied in patients with severe (Child Pugh Class C) hepatic impairment.

5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology or repeated dose toxicity.

Genotoxicity

No mutagenic or genotoxic effects of tepotinib were observed in *in vitro* and *in vivo* studies. However, the maximally feasible dose used in the *in vivo* micronucleus test in rats provided an estimated systemic exposure close to 3-fold lower than the clinical plasma exposure. The major circulating metabolite was shown to be non-mutagenic.

Carcinogenicity

No studies have been performed to evaluate the carcinogenic potential of tepotinib.

Reproduction toxicity

In a first oral embryo-foetal development study, pregnant rabbits received doses of 50, 150, and 450 mg tepotinib hydrochloride hydrate per kg per day during organogenesis. The dose of 450 mg per kg (approximately 61% of the human exposure at the recommended dose of TEPMETKO 450 mg once daily based on AUC) was discontinued due to severe maternal toxic effects. In the 150 mg per kg group (approximately 40% of the human exposure at the 450 mg clinical dose), two animals aborted and one animal died prematurely. Mean foetal body weight was decreased at doses of ≥ 150 mg per kg per day. A dose-dependent increase of skeletal malformations, including malrotations of fore and/or hind paws with concomitant misshapen scapula and/or malpositioned clavicle and/or calcaneus and/or talus, were observed at 50 mg per kg (approximately 14% of the human exposure at the 450 mg clinical dose) and 150 mg per kg per day.

In the second embryo-foetal development study, pregnant rabbits received oral doses of 0.5, 5, and 25 mg tepotinib hydrochloride hydrate per kg per day during organogenesis. Two malformed foetuses with malrotated hind limbs were observed: one in the 5 mg per kg group (approximately 0.21% of the human exposure at the recommended dose of TEPMETKO 450 mg once daily based on AUC) and one in the 25 mg per kg group (approximately 1.3% of the human exposure at the 450 mg clinical dose), together with a generally increased incidence of foetuses with hind limb hyperextension.

Fertility studies of tepotinib to evaluate the possible impairment of fertility have not been performed. No morphological changes in male or female reproductive organs were seen in the repeat-dose toxicity studies in rats and dogs, except for reduced secretion in seminal vesicles of male rats in a 4-week repeat-dose toxicity study at 450 mg per kg per day (comparable to human exposure at the 450 mg clinical dose).

Environmental risk assessment

Environmental risk assessment studies have shown that tepotinib has the potential to be very persistent and toxic to the environment.

6. PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Tablet core

Mannitol
Colloidal anhydrous silica
Crospovidone
Magnesium stearate
Microcrystalline cellulose

Film-coating

Polyvinyl alcohol
Titanium dioxide (E171)
Polyethylene glycol
Talc
Red iron oxide (E172)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

3 years.

6.4 Special precautions for storage

This medicinal product does not require special storage conditions.

6.5 Nature and contents of container

Aluminium/Polyvinyl chloride-polyethylene-polyvinylidene chloride-polyethylene-polyvinyl chloride (Al/PVC-PE-PVDC-PE-PVC) blister. Pack of 60 film-coated tablets.

6.6 Special precautions for disposal

This medicinal product may pose a risk to the environment (see section 5.3). Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Merck Europe B.V.
Gustav Mahlerplein 102
1082 MA Amsterdam
The Netherlands

8. MARKETING AUTHORISATION NUMBER

EU/1/21/1596/001

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 16 February 2022

10. DATE OF REVISION OF THE TEXT

04/2026

Detailed information on this medicinal product is available on the website of the European Medicines Agency <https://www.ema.europa.eu>.